{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T16:30:06Z","timestamp":1721406606950},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T00:00:00Z","timestamp":1409702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00280-014-2569-7","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T16:01:42Z","timestamp":1409673702000},"page":"955-967","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms"],"prefix":"10.1007","volume":"74","author":[{"given":"William D.","family":"Figg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Monga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Headlee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avni","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy H.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody","family":"Peer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Messman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusri A.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Murgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Melillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin C.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Kalnitskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian M.","family":"Senderowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Hollingshead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan G.","family":"Arbuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Sausville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,3]]},"reference":[{"issue":"1","key":"2569_CR1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0005-2760(97)00163-X","volume":"1390","author":"G Arthur","year":"1998","unstructured":"Arthur G, Bittman R (1998) The inhibition of cell signaling pathways by antitumor ether lipids. Biochim Biophys Acta Lipids Lipid Metab 1390(1):85\u2013102","journal-title":"Biochim Biophys Acta Lipids Lipid Metab"},{"issue":"3","key":"2569_CR2","first-page":"423","volume":"75","author":"DBJ Herrmann","year":"1985","unstructured":"Herrmann DBJ (1985) Changes in cellular lipid-synthesis of normal and neoplastic-cells during cytolysis induced by alkyl lysophospholipid analogs. J Natl Cancer Inst 75(3):423\u2013430","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2569_CR3","first-page":"4681","volume":"39","author":"M Modolell","year":"1979","unstructured":"Modolell M, Andreesen R, Pahlke W, Brugger U, Munder PG (1979) Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res 39(11):4681\u20134686","journal-title":"Cancer Res"},{"issue":"2","key":"2569_CR4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0360-3016(00)01476-0","volume":"49","author":"GA Ruiter","year":"2001","unstructured":"Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ (2001) Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol 49(2):415\u2013419","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"2569_CR5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0008-8749(91)90072-J","volume":"137","author":"K Vehmeyer","year":"1991","unstructured":"Vehmeyer K, Scheurich P, Eibl H, Unger C (1991) Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin-2. Cell Immunol 137(1):232\u2013238","journal-title":"Cell Immunol"},{"issue":"15","key":"2569_CR6","first-page":"4458","volume":"50","author":"MJ Seewald","year":"1990","unstructured":"Seewald MJ, Olsen RA, Sehgal I, Melder DC, Modest EJ, Powis G (1990) Inhibition of growth factor-dependent inositol phosphate Ca-2\u00a0+\u00a0signaling by antitumor ether lipid analogs. Cancer Res 50(15):4458\u20134463","journal-title":"Cancer Res"},{"issue":"10","key":"2569_CR7","first-page":"2730","volume":"60","author":"D Strassheim","year":"2000","unstructured":"Strassheim D, Shafer SH, Phelps SH, Williams CL (2000) Small cell lung carcinoma exhibits greater phospholipase C-beta 1 expression and edelfosine resistance compared with non-small cell lung carcinoma. Cancer Res 60(10):2730\u20132736","journal-title":"Cancer Res"},{"issue":"3","key":"2569_CR8","first-page":"807","volume":"51","author":"F Uberall","year":"1991","unstructured":"Uberall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and protein-kinase-C activity. Cancer Res 51(3):807\u2013812","journal-title":"Cancer Res"},{"issue":"42","key":"2569_CR9","doi-asserted-by":"crossref","first-page":"39541","DOI":"10.1074\/jbc.M203176200","volume":"277","author":"AH Luit van der","year":"2002","unstructured":"van der Luit AH, Budde M, Ruurs P, Verheij M, van Blitterswijk WJ (2002) Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 277(42):39541\u201339547","journal-title":"J Biol Chem"},{"key":"2569_CR10","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/S0959-8049(99)81109-5","volume":"35","author":"GA Ruiter","year":"1999","unstructured":"Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ (1999) Alkyl-lysophospholipids activate the SAPK\/JNK signaling pathway and enhance radiation-induced apoptosis. Eur J Cancer 35:S179","journal-title":"Eur J Cancer"},{"issue":"5","key":"2569_CR11","first-page":"1401","volume":"62","author":"V Patel","year":"2002","unstructured":"Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM (2002) Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 62(5):1401\u20131409","journal-title":"Cancer Res"},{"issue":"11","key":"2569_CR12","first-page":"1093","volume":"2","author":"SB Kondapaka","year":"2003","unstructured":"Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2(11):1093\u20131103","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2569_CR13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00001813-200302000-00011","volume":"14","author":"GA Ruiter","year":"2003","unstructured":"Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M (2003) Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt\/PKB survival pathway. Anticancer Drugs 14(2):167\u2013173","journal-title":"Anticancer Drugs"},{"issue":"4","key":"2569_CR14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2174\/1871520614666140309225912","volume":"14","author":"J Fensterle","year":"2014","unstructured":"Fensterle J, Aicher B, Seipelt I, Teifel M, Engel J (2014) Current view on the mechanism of action of perifosine in cancer. Anticancer Agents Med Chem 14(4):629\u2013635","journal-title":"Anticancer Agents Med Chem"},{"issue":"1\u20132","key":"2569_CR15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF01831480","volume":"23","author":"H Naundorf","year":"1992","unstructured":"Naundorf H, Rewasowa EC, Fichtner I, Buttner B, Becker M, Gorlich M (1992) Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives. Breast Cancer Res Treat 23(1\u20132):87\u201395","journal-title":"Breast Cancer Res Treat"},{"issue":"1A","key":"2569_CR16","first-page":"37","volume":"17","author":"O Safa","year":"1997","unstructured":"Safa O, Parkin SM, Matthew AM, Bibby MC (1997) Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts. Anticancer Res 17(1A):37\u201343","journal-title":"Anticancer Res"},{"issue":"4","key":"2569_CR17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0959-8049(05)80142-X","volume":"29A","author":"AST Planting","year":"1993","unstructured":"Planting AST, Stoter G, Verweij J (1993) Phase-Ii study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal-cancer. Eur J Cancer 29A(4):518\u2013519","journal-title":"Eur J Cancer"},{"issue":"8","key":"2569_CR18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/BF01211805","volume":"118","author":"J Verweij","year":"1992","unstructured":"Verweij J, Planting A, Vanderburg M, Stoter G (1992) A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumors. J Cancer Res Clin Oncol 118(8):606\u2013608","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2569_CR19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0959-8049(93)90177-H","volume":"29A","author":"J Verweij","year":"1993","unstructured":"Verweij J, Krzemieniecki K, Kok T et al (1993) Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult\u2014an EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer 29A(2):208\u2013209","journal-title":"Eur J Cancer"},{"issue":"6","key":"2569_CR20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0190-9622(93)70275-X","volume":"29","author":"R Dummer","year":"1993","unstructured":"Dummer R, Krasovec M, Roger J, Sindermann H, Burg G (1993) Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas\u2014results of a phase-I\/II study. J Am Acad Dermatol 29(6):963\u2013970","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"2569_CR21","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2001.19.21.4150","volume":"19","author":"R Leonard","year":"2001","unstructured":"Leonard R, Hardy J, van Tienhoven G et al (2001) Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 19(21):4150\u20134159","journal-title":"J Clin Oncol"},{"issue":"24","key":"2569_CR22","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","volume":"341","author":"TK Jha","year":"1999","unstructured":"Jha TK, Sundar S, Thakur CP et al (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341(24):1795\u20131800","journal-title":"N Engl J Med"},{"issue":"3","key":"2569_CR23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0959-8049(97)89020-X","volume":"33","author":"P Hilgard","year":"1997","unstructured":"Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J (1997) D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33(3):442\u2013446","journal-title":"Eur J Cancer"},{"issue":"12","key":"2569_CR24","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0959-8049(02)00127-2","volume":"38","author":"M Crul","year":"2002","unstructured":"Crul M, Rosing H, de Klerk GJ et al (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38(12):1615\u20131621","journal-title":"Eur J Cancer"},{"issue":"2","key":"2569_CR25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0378-4347(01)00231-6","volume":"759","author":"EW Woo","year":"2001","unstructured":"Woo EW, Messmann R, Sausville EA, Figg WD (2001) Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. J Chromatogr B 759(2):247\u2013257","journal-title":"J Chromatogr B"},{"key":"2569_CR26","first-page":"67","volume":"34","author":"M Traiser","year":"1998","unstructured":"Traiser M, Reichert S, Voss A (1998) Current development status of the second generation alkylphosphocholine analog perifosine. Drugs Today 34:67\u201371","journal-title":"Drugs Today"},{"issue":"5","key":"2569_CR27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ejca.2009.12.028","volume":"46","author":"C Unger","year":"2010","unstructured":"Unger C, Berdel W, Hanauske AR, Sindermann H, Engel J, Mross K (2010) First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer 46(5):920\u2013925","journal-title":"Eur J Cancer"},{"issue":"22","key":"2569_CR28","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/1078-0432.CCR-03-0406","volume":"10","author":"L Ummersen Van","year":"2004","unstructured":"Van Ummersen L, Binger K, Volkman J et al (2004) A phase I trial of perifosine (NSC 639966) on a loading dose\/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10(22):7450\u20137456","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2569_CR29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4161\/cbt.4.10.2064","volume":"4","author":"EM Posadas","year":"2005","unstructured":"Posadas EM, Gulley J, Arlen PM et al (2005) A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 4(10):1133\u20131137","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"2569_CR30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10637-005-1157-4","volume":"23","author":"DS Ernst","year":"2005","unstructured":"Ernst DS, Eisenhauer E, Wainman N et al (2005) Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23(6):569\u2013575","journal-title":"Invest New Drugs"},{"issue":"24","key":"2569_CR31","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1002\/cncr.27668","volume":"118","author":"DC Cho","year":"2012","unstructured":"Cho DC, Hutson TE, Samlowski W et al (2012) Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 118(24):6055\u20136062","journal-title":"Cancer"},{"issue":"4","key":"2569_CR32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2141.2012.09173.x","volume":"158","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC (2012) Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed\/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol 158(4):472\u2013480","journal-title":"Br J Haematol"},{"issue":"10","key":"2569_CR33","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","volume":"107","author":"T Hideshima","year":"2006","unstructured":"Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107(10):4053\u20134062","journal-title":"Blood"},{"issue":"32","key":"2569_CR34","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1200\/JCO.2010.33.9788","volume":"29","author":"PG Richardson","year":"2011","unstructured":"Richardson PG, Wolf J, Jakubowiak A et al (2011) Perifosine plus bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I\/II trial. J Clin Oncol 29(32):4243\u20134249","journal-title":"J Clin Oncol"},{"key":"2569_CR35","doi-asserted-by":"crossref","unstructured":"Richardson PG, Nagler A, Ben-Yehuda D, Badros AZ, Hari P, Hajek R, Spicka I, Kaya H, Le Blanc R, Yoon S\u2013S, Kim K, Martinez-Lopez J, Mittelman M, Shpilberg O, Tothova E, Laubach JP, Ghobrial IM, Leiba M, Gatt ME, Sportelli P, Chen M, Anderson KC (2013) Randomized placebo-controlled phase III study of perifosine combined with bortezomib and dexamethasone in relapsed, refractory multiple myeloma patients previously treated with bortezomib. ASH 2013 annual meeting abstract 3189 (poster presentation)","DOI":"10.1182\/blood.v122.21.3189.3189"},{"issue":"33","key":"2569_CR36","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1200\/JCO.2011.36.1980","volume":"29","author":"JC Bendell","year":"2011","unstructured":"Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, Sportelli P, Gardner L, Richards DA (2011) Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 29(33):4394\u20134400","journal-title":"J Clin Oncol"},{"key":"2569_CR37","doi-asserted-by":"crossref","unstructured":"Bendell JC, Senzer NN, Richards DA, Firdaus I, Lockhart AC, Cohn AL, Saleh MN, Gardner LR, Sportelli P (2012) Cathy eng. Results of the X-PECT study: a phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 30(suppl: abstr LBA3501)","DOI":"10.1200\/jco.2012.30.18_suppl.lba3501"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2569-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2569-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2569-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T04:07:44Z","timestamp":1650082064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2569-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,3]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["2569"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2569-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,3]]}}}